Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.

Cancer ups risk of incident diabetes

Tristan Manalac
14 Jun 2018

Cancer appears to independently increase the risk of diabetes, regardless of traditional risk factors, according to a recent Korea study.

“The increased risk of diabetes was evident shortly after cancer development, was strongest in the first 2 years after cancer diagnosis and remained elevated throughout the rest of follow-up,” said researchers.

Over 3,492,935.6 person-years of follow-up in 494,189 adults (mean age 41.8±12.5 years; 50 percent female), 15,130 individuals developed cancer. [JAMA Oncol 2018;doi:10.1001/jamaoncol.2018.1684]

Cases of incident diabetes were reported in 26,610 individuals, 834 of which occurred after incident cancer diagnosis, yielding an incidence rate of 17.4 per 1,000 person-years. The corresponding incidence rate of diabetes in participants without cancer was 7.5 per 1,000 person-years.

An age- and sex-adjusted proportional hazards regression model showed that there was a significant association between incident diabetes and the development of cancer (hazard ratio [HR], 1.36; 95 percent CI, 1.27–1.46). This relationship remained significant even after adjusting for precancer diabetes risk factors and comorbidities (HR, 1.35; 1.26–1.45; p<0.001 for both).

Analysis by time since cancer development showed that the risk of diabetes was highest in the first 2 years after cancer diagnosis (HR, 1.47; 1.35–1.60) but remained significant even after 6–10 years after (HR, 1.19; 1.00-1.43; p<0.001 for both).

Type of cancer also had an effect on incident diabetes risk. Pancreatic (HR, 5.15; 3.32–7.99), kidney (HR, 2.06; 1.34–3.16) and liver (HR, 1.95; 1.50–2.54) cancers yielded the highest risk, while ovarian (HR, 1.07; 0.48–2.38) and prostate (HR, 0.81; 0.55–1.20) cancers were not associated with the likelihood of diabetes development.

“The increased risk of diabetes after cancer may be related to cancer-management interventions,” explained researchers, further noting that corticosteroids, widely used in different cancer treatments, have been shown to induce hyperglycaemia and diabetes development, potentially through reducing insulin sensitivity. [Endocr Pract 2009;15:469-474]

Chemotherapeutic agents like tamoxifen and L-asparaginase have likewise been shown to increase the risk of diabetes, researchers continued. “In our study, the increased risk of diabetes seemed to be highest in the period immediately after cancer development, further suggesting a role for toxicity of cancer treatments in diabetes development.”

For the study, researchers accessed the National Health Insurance Service-National Sample Cohort to collect information on participant baseline characteristics, comorbidities, cancer diagnoses and diabetes development. Using incident cancer as an exposure, researchers evaluated incident type 2 diabetes as the main study outcome.

“Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.